(0.28%) 5 195.17 points
(0.18%) 38 920 points
(0.18%) 16 379 points
(0.52%) $78.89
(-0.27%) $2.19
(-0.44%) $2 320.90
(-0.28%) $27.54
(2.41%) $988.20
(0.09%) $0.929
(0.68%) $10.90
(0.36%) $0.799
(-0.01%) $91.34
Live Chart Being Loaded With Signals
BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden...
Stats | |
---|---|
本日の出来高 | 83 310.00 |
平均出来高 | 150 761 |
時価総額 | 17.68B |
EPS | SEK0 ( 2024-02-14 ) |
次の収益日 | ( SEK-0.750 ) 2024-05-17 |
Last Dividend | SEK0 ( N/A ) |
Next Dividend | SEK0 ( N/A ) |
P/E | 77.45 |
ATR14 | SEK0.345 (0.17%) |
ボリューム 相関
BioArctic AB (publ) 相関
10 最も正の相関 |
---|
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
BioArctic AB (publ) 相関 - 通貨/商品
BioArctic AB (publ) 財務諸表
Annual | 2023 |
収益: | SEK616.00M |
総利益: | SEK346.32M (56.22 %) |
EPS: | SEK2.60 |
FY | 2023 |
収益: | SEK616.00M |
総利益: | SEK346.32M (56.22 %) |
EPS: | SEK2.60 |
FY | 2022 |
収益: | SEK228.29M |
総利益: | SEK153.97M (67.44 %) |
EPS: | SEK-0.130 |
FY | 2021 |
収益: | SEK23.15M |
総利益: | SEK-31.92M (-137.91 %) |
EPS: | SEK-1.360 |
Financial Reports:
No articles found.
BioArctic AB (publ)
BioArctic AB (publ), a research-intensive biopharmaceutical company, develops biological drugs for patients with neurodegenerative disorders in Sweden. The company develops BAN2401, an immunotherapy, which is in Phase III clinical trials targeting the toxic amyloid-beta oligomers/protofibrils in Alzheimer's disease; and is in preclinical trials for treating Down's syndrome with dementia and traumatic brain injury, as well as BAN2401 Back-up, a disease modifying antibody treatment that is in late preclinical Phase for patients with early Alzheimer's disease. It also develops ABBV-0805, a monoclonal antibody for treating Parkinson's disease; and SC0806, a biodegradable device that is in Phase I/II clinical trial for spinal cord injuries. In addition, the company develops imaging and biochemical biomarkers for Alzheimer's and Parkinson's disease; and blood-brain-barrier technology that enables the passage of antibodies and other substances into the brain through the blood brain barrier, as well as focuses on developing ND3014 antibodies for treating neurodegenerative disorders; AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603 for the treatment of Alzheimer's disease; and PD1601 and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was founded in 1992 and is based in Stockholm, Sweden.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。